Bleakley Financial Group LLC Sells 5,074 Shares of Liquidia Co. (NASDAQ:LQDA)

Bleakley Financial Group LLC lessened its holdings in Liquidia Co. (NASDAQ:LQDA) by 16.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,692 shares of the company’s stock after selling 5,074 shares during the quarter. Bleakley Financial Group LLC’s holdings in Liquidia were worth $257,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Creative Planning bought a new position in shares of Liquidia in the 3rd quarter valued at about $170,000. Sapient Capital LLC acquired a new position in Liquidia in the third quarter valued at about $1,336,000. SG Americas Securities LLC acquired a new position in Liquidia in the third quarter valued at about $210,000. Whitcomb & Hess Inc. lifted its stake in Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the period. Finally, Bluefin Capital Management LLC acquired a new position in Liquidia in the second quarter valued at about $277,000. Institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,526 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the transaction, the insider now directly owns 204,857 shares of the company’s stock, valued at approximately $2,292,349.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the sale, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,384 shares of company stock valued at $256,990. 31.60% of the stock is owned by insiders.

Liquidia Stock Down 1.1 %

NASDAQ:LQDA opened at $11.08 on Thursday. Liquidia Co. has a twelve month low of $6.06 and a twelve month high of $16.99. The company has a market cap of $846.67 million, a P/E ratio of -7.10 and a beta of 0.22. The business has a 50 day moving average price of $10.29 and a two-hundred day moving average price of $11.82.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, analysts anticipate that Liquidia Co. will post -1.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

LQDA has been the topic of several analyst reports. Bank of America cut their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. HC Wainwright lowered their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Needham & Company LLC restated a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. Finally, BTIG Research lowered their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).